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Acquiring iron (Fe) is critical to the metabolism and growth ofMycobacterium tuberculosis. Disruption of Fe metabolism is a
potential approach for novel antituberculous therapy. Gallium (Ga) has many similarities to Fe. Biological systems are often un-
able to distinguish Ga3 from Fe3. Unlike Fe3, Ga3 cannot be physiologically reduced to Ga2. Thus, substituting Ga for Fe
in the active site of enzymes may render them nonfunctional. We previously showed that Ga inhibits growth ofM. tuberculosis
in broth and within cultured humanmacrophages. We now report that Ga(NO3)3 shows efficacy in murine tuberculosis models.
BALB/c SCIDmice were infected intratracheally withM. tuberculosis, following which they received daily intraperitoneal saline,
Ga(NO3)3, or NaNO3. All mice receiving saline or NaNO3 died. All Ga(NO3)3-treated mice survived.M. tuberculosis CFU in the
lungs, liver, and spleen of the NaNO3-treated or saline-treated mice were significantly higher than those in Ga-treated mice.
When BALB/c mice were substituted for BALB/c SCIDmice as a chronic (nonlethal) infection model, Ga(NO3)3 treatment signif-
icantly decreased lung CFU. To assess the mechanism(s) whereby Ga inhibits bacterial growth, the effect of Ga onM. tuberculo-
sis ribonucleotide reductase (RR) (a key enzyme in DNA replication) and aconitase activities was assessed. Ga decreasedM. tu-
berculosis RR activity by 50 to 60%, but no additional decrease in RR activity was seen at Ga concentrations that completely
inhibited mycobacterial growth. Ga decreased aconitase activity by 90%. Ga(NO3)3 shows efficacy in murineM. tuberculosis in-
fection and leads to a decrease in activity of Fe-dependent enzymes. Additional work is warranted to further define Ga’s mecha-
nism of action and to optimize delivery forms for possible therapeutic uses in humans.
Mycobacterium tuberculosis is an intracellular pathogen of hu-man macrophages. It infects the human respiratory system,
causing the clinical entity of tuberculosis (TB) (1). In 2011, M.
tuberculosis was responsible for approximately 8.7 million infec-
tions and 1.4 million deaths worldwide (2). Although effective
antibiotic treatment is available for drug-susceptible M. tubercu-
losis, it requires administration of multiple antibiotics for many
months. However, antibiotic resistance is becoming an increasing
and major challenge in form of multiple-drug-resistant tubercu-
losis (MDR-TB) and extensively drug-resistant (XDR-TB) infec-
tions. Hence, the search for new therapeutic approaches is a pri-
ority for the scientific community.
Ferric iron (Fe3) is essential for the growth of most microor-
ganisms, including M. tuberculosis, as the metal is utilized as a
constituent of enzymes and proteins that are critical to various
metabolic and DNA-synthetic pathways (3). Our laboratory and
others have shown that disruption of ironmetabolism inhibits the
growth ofM. tuberculosis and other bacteria regardless of whether
they are growing extracellularly or within human macrophages
(4–6). The ability of pathogens to obtain iron from host sources
such as transferrin, lactoferrin, ferritin, and heme or other iron-
containing proteins is considered to be a key virulence factor (4,
5). In animal models, the pathogenicity and virulence of many
pathogens, including M. tuberculosis and Mycobacterium avium,
are considerably enhanced as iron availability is increased in the
host (7–9). Clinical data suggest that this is the case with human
tuberculosis as well (8, 10). Furthermore, new insights into iron
acquisition mechanisms by M. tuberculosis are being uncovered
(11, 12).
Given the importance of iron acquisition to pathogenesis, bac-
terial iron metabolism is an attractive target for therapeutic drug
development. Iron chelation approaches have been attempted but
have not yet led to successful therapies (13, 14). We and others
have pursued an alternative approach in which gallium (Ga),
which has remarkable physicochemical similarity to iron, is used
to corrupt the bacterial iron acquisition and utilization process.
Gallium, which exists in nature as Ga3, binds to most ferric
iron-binding proteins and chelating agents with an affinity similar
to that of iron. However, Ga3 is not reducible under physiolog-
ical conditions, whereas Fe3 is readily reduced to Fe2 (15). The
ability to redox cycle between these two oxidation states is critical
to the ability of iron to catalyze biochemical reactions. Thus, if
cells take up and insert Ga3 into active sites of Fe-dependent
enzymes, the enzymes are rendered inactive. This property led to
the development and FDA approval of Ga-based therapy for the
treatment of hypercalcemia of malignancy, in which Ga inhibits
ribonucleotide reductase (RR) activity in malignant cells (15).
We previously demonstrated that the presence of Ga inhibits
the in vitro growth of M. tuberculosis, regardless of whether the
mycobacteria are growing extracellularly or within cultured hu-
man macrophages (6). A series of studies by our laboratory and
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others demonstrated that Ga possesses antimicrobial potency
against a variety of human pathogens (3, 5, 6, 16–18). Disruption
of bacterial iron acquisition/utilization has been shown to corre-
late with the ability of Ga to inhibitM. tuberculosis growth as well
as that of other organisms (3, 5, 6, 16, 17). However, the key
aspects ofM. tuberculosis ironmetabolism affected by Ga have not
beenwell defined. Furthermore,whether the in vitro antimicrobial
activity of Ga against M. tuberculosis translates to in vivo efficacy
has not been examined.
Both delineation of the mechanism of action and demonstra-
tion of efficacy in vivo are critical next steps in the further devel-
opment of a Ga-based approach to therapy of tuberculosis. The
purpose of the present study was to assess the ability of Ga admin-
istration to inhibit the growth of virulentM. tuberculosis in vivo by
using two separate murine models of pulmonary tuberculosis. In
addition, we sought insight into keymicrobial targets disrupted by
Ga therapy.
MATERIALS AND METHODS
Materials. Ga(NO3)3, sodium citrate, acetate, HEPES, dithiothreitol
(DTT), and lysozymewere purchased fromSigma-Aldrich, St. Louis,MO.
Lysis buffer (B-PER bacterial protein extraction reagents) was purchased
from Fisher Scientific, Pittsburg, PA. Additional reagents and their
sources are as follows: RNase A, NDP kinase, and DNase were obtained
from Invitrogen, Grand Island, NY; ATP was obtained from Alexis Bio-
chemicals, Farmingdale, NY; herring sperm DNA (0.1 to 3 kb) was ob-
tained from Promega, Madison, WI; Klenow polymerase and a random
6-mer primer were obtained from New England BioLabs, Ipswich, MA;
andDE-81 filter discs were obtained fromGEHealthcare, Pittsburgh, PA.
A bicinchoninic acid (BCA) kit was purchased from Thermo Fisher Sci-
entific, Rockford, IL.
Mycobacterium tuberculosis strains and cultivation.Mycobacterium
tuberculosis strains H37Ra (ATCC 25177), H37Rv (ATCC 27294), and Erd-
man (ATCC 35801) were cultivated on 7H11 agar plates for 10 days. They
were then harvested into 7H9mediumcontaining 10mMHEPES, to form
predominantly single-cell suspensions (19), and used shortly thereafter.
Infection of mice with M. tuberculosis. BALB/c and BALB/c SCID
mice, 6 to 8 weeks old, were purchased from Jackson Laboratories (Bar
Harbor, ME). BALB/c mice are relatively susceptible to infection withM.
tuberculosis. Mice were maintained under sterile conditions in microiso-
lator cages in a barrier facility and supplied with sterilized food and water.
All animal procedures were approved by the University of Cincinnati
Institutional Animal Care and Use Committee.
Mice were infected intratracheally (i.t.) with the desired numbers of
CFU of either the H37Rv or Erdman strain ofM. tuberculosis suspended in
50 l Hanks’ balanced salt solution (HBSS) in a class III biohazard safety
cabinet andweremaintained in the biosafety level 3 (BSL3) animal facility
at the University of Cincinnati. Infectedmice were then treated daily with
50 l of phosphate-buffered saline (PBS), Ga nitrate, or sodium nitrate
intraperitoneally (i.p.). At specific times followingM. tuberculosis admin-
istration, mice were sacrificed, and the burden of M. tuberculosis was de-
termined by counting CFU in lung homogenates. We infected SCIDmice
with 100 CFU of M. tuberculosis (strain H37Rv) bacteria i.t., followed by
daily i.p. administration of 10 mg/kg of body weight Ga(NO3)3, a dosage
that was previously shown to be well tolerated (10 mg/kg) (16, 17). Con-
trolmice received either saline or amolar equivalent ofNO3
 (NaNO3) to
that provided by Ga(NO3)3, the latter as a control for any possible effects
of NO3
. The mice were then observed daily. The concentration of Ga
used in this study (10 mg/kg) is in the range of that achievable in vivo and
found to be safe for human use (3, 20).
Determination ofM. tuberculosisCFU in tissue organs.To assessM.
tuberculosis numbers in the tissues of the infected mice, at specified time
points, lungs, spleen, and liver were removed aseptically, cut into small
pieces, and homogenized. Viable M. tuberculosis bacteria in the tissue
homogenate were quantified by determining CFU as described in our
previous studies (6). Briefly, serial dilutions of tissue homogenates were
plated in duplicate onto 7H11 Middlebrook agar in 6-well plates. The
inoculated agar plates were dried at room temperature and incubated in a
37°C incubator for up to 3 weeks, at which time colonies were counted.
The results were expressed as means standard deviations of tissue CFU
per whole organ under each experimental condition and for different
treatments.
Human monocyte-derived macrophage preparation. Peripheral ve-
nous blood was obtained from healthy adult volunteers according to a
University of Cincinnati College of Medicine-approved institutional re-
view board (IRB) protocol. Mononuclear cells were separated by Ficoll-
Hypaque centrifugation and cultured in RPMI 1640 (Gibco, Grand Is-
land, NY) supplemented with 20% autologous human serum for 5 days in
Teflon wells in a 5% CO2 atmosphere at 37°C to allow for differentiation
into monocyte-derived macrophages (MDM). MDM monolayers were
then maintained in 24- or 6-well culture plates, supplemented with 20%
autologous serum, and incubated at 37°C for 1 day prior to incubation
with M. tuberculosis.
Preparation of cell extract for the RR assay. The protocol for prepa-
ration of cell extracts was adapted from the original protocol by Jong et al.
for the RR assay (21). M. tuberculosis strain H37Ra was inoculated into
definedMiddlebrook 7H9 (D7H9)mediumwith andwithout 1Mferric
ammonium sulfate and with and without Ga(NO3)3 (10 to 100M). The
bacteria were then incubated overnight at 37°C with shaking, with mon-
itoring of the optical density (OD) (at 600 nm). The suspension was cen-
trifuged at 10,000 g for 10 min at 4°C and washed twice in buffer I (500
mM, pH 7.2). The resulting pellet was weighed and finally suspended in
lysis buffer (B-PER) containing 50 mg/ml lysozyme, 0.2 mg/ml RNase A,
DNase, and an antiprotease cocktail at 4 ml/g of wet bacterial pellet. The
suspensionwas rocked for 30min at room temperature and centrifuged at
12,000  g for 10 min at 25°C, and the supernatant was decanted. The
pellet was homogenized on ice by using a glass homogenizer. The homog-
enate was centrifuged at 16,000 g for 20min at 4°C, and the supernatant
was collected. Two hundred microliters of the supernatant was then
loaded onto a Sephadex G-25 column that was preequilibrated with ice-
cold buffer II (50 mM HEPES [pH 7.2], 2 mM DTT) and centrifuged at
1,500 g for 4 min at 4°C to remove endogenous nucleotides. The flow-
through was collected, and the protein concentration was determined by
using a BCA kit.
The RR reaction mixture, consisting of 50 mM HEPES (pH 7.2), 18
mMDTT, 12 mMMg acetate, 6 mM ATP, and 100 pmol [14C]CDP (405
mCi/mmol; Moravek, Brea, CA), was prepared in Eppendorf tubes. The
reaction was initiated by the addition of 250 g of flowthrough protein
(400g), isolated fromM. tuberculosis as described above, and incubation
at 37°C for 30min. The reactionwas terminated in boilingwater for 5min.
The substrate [14C]CDP was converted to [14C]dCDP by the addition of
100 pmol of ribonucleotide reductase for 30min at 37°C and subsequently
to [14C]dCTPby the endogenousNDPkinase in the reactionmixture. The
mixture was centrifuged at 16,000  g for 5 min at 25°C to remove the
precipitates, and the clear supernatant containing [14C]dCTP was used
for the DNA polymerase coupling assay.
To serve as the template for the assay, 2g herring spermDNA (0.1 to
3 kb) was mixed with 330 ng of a random 6-mer primer. The labeling
mixture contained 90mMHEPES (pH 6.6), 18 mMDTT, 10mMMgCl2,
0.2 mM deoxynucleoside triphosphate (dNTP), and 5 units of Klenow
polymerase. The boiled RR reaction mixture containing [14C]dCTP was
added to thismixture and incubated at room temperature for 30min. The
reactionwas terminated by spotting 40l of themixture ontoDE-81 filter
discs. The filters were air dried overnight and washed with 5% Na2HPO4
for 5 min by shaking gently on a platform rotator, and the medium was
removed. Washing was repeated twomore times with 5%Na2HPO4 for 2
min each. The filters were then rinsed with distilled water twice, followed
by 95% ethanol once. The paper was dried under a heat lamp. The com-
pletely dried filter papers were transferred into a vial with 20 ml Aquasol
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for scintillation counting. Two microliters (100 pmol) of [14C]CDP was
spotted onto one of the discs for total counts. A sham control that has all
other reagents, except the protein lysate, was included in the reaction. This
value, representing a random reaction, was subtracted from other counts.
Aconitase assay. Bacteria were cultured, collected, and lysed as de-
scribed above for the RR assay. Aconitase activity was assayed in the re-
sulting cell lysate by according to methods described previously by Ken-
nedy et al., by monitoring the conversion of isocitrate to cis-aconitate, as
indicated by the increase in the absorbance at 240 nm (22). The assay was
performed with 20 mM KH2PO4 buffer (pH 7.7) containing 250 M
isocitrate.
Data analysis.Data were analyzed and statistical tests were performed
by using GraphPad Prism version 4 for Windows (GraphPad Software,
San Diego, CA). Student’s t test was employed for analysis of two groups.
To determine differences between three ormoremeans, we used one-way
analysis of variance (ANOVA) with Bonferroni post hoc tests. Error bars
represent means  standard errors of the means (SEM). All statistical
analyses were considered significant at aP value of0.05. A t test was used
to compare survival curves.
RESULTS
Gallium is efficacious in a SCIDmouseM. tuberculosis infection
model.We have shown previously that Ga disrupts iron metabo-
lism and inhibits the growth of M. tuberculosis extracellularly or
within human macrophages (6). However, a growth-inhibitory
effect in vitro does not necessarily ensure an effect in vivo. There-
fore, we sought to determine the effect of Ga on the course of M.
tuberculosis infection in an established mouse model.
In the first set of experiments, we chose to assess the effective-
ness of Ga treatment againstM. tuberculosis in a murine model in
which host defenses were unable to contain the infection: severe
combined immunodeficient (SCID)mice. Controlmice died after
25 to 40 days postinfection. However, mice receiving Ga(NO3)3
survived for up to 6 weeks, at which time they were sacrificed (Fig.
1A). The survival rate was significantly higher for Ga-treatedmice
(100% survival up to 40 days) than for the saline- or nitrite-treated
groups (P 0.05).
Given this positive result, we studied the effect of Ga using a
higher inoculum of M. tuberculosis. When the inoculum of M.
tuberculosis was increased to 106 CFU, all control mice died be-
tween days 20 and 24. Allmice receivingGa(NO3)3 remained alive
at 28 days (Fig. 1B).
We also studied the tissue burden ofM. tuberculosis by count-
ing CFU determined at the time of death for the saline- and
NaNO3-treated mice or at the time of sacrifice of the Ga(NO3)3-
treated SCID mice. Ga treatment significantly reduced the num-
ber ofM. tuberculosis CFU in the lungs relative to NaNO3 (Fig. 2)
or saline (not shown). Compared to NaNO3 controls, lung CFU
decreased by 89.9% (Fig. 2). In addition, Ga administration also
significantly decreased the level ofM. tuberculosis in other organs,
liver (97.7%) and spleen (84.8%), relative to NaNO3.
Gallium is efficacious in a BALB/c mouse M. tuberculosis
infection model. We next assessed the effectiveness of Ga in a
murine model that does not lead to lethal infection but rather
leads to a stable chronic infection. BALB/cmicewere infectedwith
100 CFU of the virulent Erdman strain of M. tuberculosis i.t., fol-
lowed by daily i.p. Ga(NO3)3. Control mice received either saline
or NaNO3, the latter at a dose equivalent to the amount of NO3
provided by administration of Ga(NO3)3. As shown in Fig. 3, in
BALB/c mice, M. tuberculosis infection led to a chronic nonlethal
infection. This resulted in a loss of weight of the animals over time
(Fig. 3A).M. tuberculosis-infected animals that received Ga exhib-
ited lessweight loss thanmice receiving saline (P 0.05) (Fig. 3A).
Compared to the saline control, initiation of Ga treatment signif-
icantly reducedM. tuberculosis growth in lung tissues (53%) at 30
days as well as in spleen (79%) (P  0.05) (Fig. 3B and C). Ga
reduced M. tuberculosis growth in the liver (49%), but the differ-
ence did not reach significance (P  0.05) (Fig. 3D). When Ga
treatment was stopped at 15 days postinfection, the bacteria re-
sumed growth, as shown by an increase in lung CFU (Fig. 3B).
Ga inhibits M. tuberculosis ribonucleotide reductase activ-
ity. Having obtained evidence of the efficacy of Ga in vivo, we
sought to obtain additional insights into the mechanism(s) by
which Ga exhibits antimycobacterial activity. Previous work
showed that Ga-mediated inhibition of M. tuberculosis growth
involved disruption of bacterial iron metabolism. The iron-de-
pendent enzyme ribonucleotide reductase (RR) is essential for
DNA synthesis (23). M. tuberculosis contains class Ib and class II
ribonucleotide reductases (24). Previous studies of eukaryotic
cells found that a major mechanism whereby Ga inhibits cell pro-
liferation is by inhibiting cellular RR activity (25). We therefore
assessed the specific effect of Ga on M. tuberculosis RR activity.
We treatedM. tuberculosisH37Ra with different concentrations
of Ga for 24 h. Inhibition of RR was seen at all levels of Ga treat-
ment. Inhibition increased significantly when the Ga concentra-
tion was doubled from 10 to 20 M (Fig. 4). However, further
inhibition was not seen when the Ga dose was increased to 50 or
FIG 1 Gallium is protective in a SCID mouse TB model. (A) Survival of the
mice as a function of time and treatment regimen. Three groups of 6- to
8-week-old BALB/c SCIDmice (3 mice/group) were infected with 100 CFU of
M. tuberculosis (strain H37Rv) i.t., following which they received daily i.p. ad-
ministration of saline, 10 mg/kg Ga(NO3)3, or NaNO3. (B) Same experiment
as in panel A but using a higherM. tuberculosis inoculum. Three groups of 6- to
8-week-old BALB/c SCIDmice (4 mice/group) were infected with 106 CFU of
M. tuberculosis (strain H37Rv) i.t., following which they received daily i.p. ad-
ministration of 10 mg/kg Ga(NO3)3 or NaNO3. The figure shows the survival
of the mice as a function of time and treatment regimen. The survival rate was
significantly higher for Ga-treatedmice (100% survival up to 40 days) than for
saline- or nitrite-treated groups (P 0.05).
Olakanmi et al.
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100 M, with a maximal inhibition of about 50% being achieved
(Fig. 4).
Gallium inhibits Mycobacterium tuberculosis aconitase ac-
tivity. Aconitase is an iron-sulfur enzyme that functions as an
electron carrier and catalyzes the isomerization of citrate to isoci-
trate via cis-aconitate in the tricarboxylic acid (TCA) cycle; thus, it
is involved inATPproduction (26). In addition, it has been shown
that M. tuberculosis aconitase binds to iron-responsive element
(IRE)-like sequences within the M. tuberculosis genome, indicat-
ing a possible role in regulating gene expression at a posttranscrip-
FIG 2 Gallium decreasesM. tuberculosis growth in lungs and dissemination to
different tissues in a SCID mouse TB model.M. tuberculosis growth following
i.t. inoculation was determined as a function of NaNO3 or Ga treatment for
SCID mice in the experiment shown in Fig. 1B. Mice were infected with 106
CFU. Tissues were homogenized, and the numbers of M. tuberculosis CFU in
the lungs (A), spleens (B), and liver (C)were determined at the time of death of
the animals or when then they were sacrificed after infection, as described in
Materials and Methods. Asterisks indicate a P value of0.05.
FIG 3 Gallium prevents weight loss and decreases M. tuberculosis growth in
lungs and other organs ofM. tuberculosis-infected BALB/c mice. BALB/c mice
were infected with 100 CFU of the virulent M. tuberculosis Erdman strain i.t.,
followed by daily intraperitoneal administration of Ga(NO3)3 (10 mg/kg),
which was initiated immediately following infection (n	 5 each group). For
somemice, Ga therapy was stopped after 15 days. Control mice received either
NaNO3 or saline. (A) M. tuberculosis infection led to a chronic nonlethal in-
fection that resulted in a loss of weight of the animals over time. Animals that
received Ga for either for the full 30 days or the initial 15 days before sacrifice
exhibited less weight loss than mice receiving saline. (B)WhenM. tuberculosis
CFU in the lungs were determined at 30 days postinfection, mice receiving Ga
for the full 30 days showed a significant reduction of CFU (P 0.05) relative to
the saline-treated control. When Ga was stopped after 15 days, a significant
increase in CFU was still observed in mouse lungs relative to the control (P
0.05). (C) A significant reduction in M. tuberculosis CFU was also seen in the
spleens of mice treated with Ga for 30 days (P  0.05) compared to NaNO3
controls. In liver, there was a reduction, but it did not reach statistical signifi-
cance (P 0.05). Asterisks indicate a P value of0.05.
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tional level (27). Therefore, we explored the effect of Ga treatment
on the activity of aconitase in M. tuberculosis. M. tuberculosis was
incubated in defined 7H9 medium alone or with the desired con-
centrations of Ga(NO3)3, following which the bacteria were har-
vested and aconitase activitywas determined. AGa-mediated con-
centration-dependent inhibition of M. tuberculosis aconitase
activity was observed (Fig. 5).
DISCUSSION
Drug-resistant tuberculosis has become a major therapeutic chal-
lenge (28), and the search for an alternative effective treatment is
an urgent necessity. Iron is critical for the growth/metabolism of
most bacteria (29), including M. tuberculosis (30), making iron
metabolism an ideal target for novel therapy. Gallium is a transi-
tion metal that has been developed as a therapeutic entity for
cancer because it disrupts iron metabolism of eukaryotic cells. Ga
can interfere with RR activity and inhibit DNA synthesis (31). It
was also shown previously that Ga(NO3)3 can inhibit protein ty-
rosine phosphatase (PTPase) in Jurkat human T-cell leukemia
cells and HT-29 human colon cancer cells (32). In spite of these
biochemical effects, citrate-buffered Ga(NO3)3 is an FDA-ap-
proved therapy for the treatment of hypercalcemia of malignancy
and has been well tolerated (3). The primary toxicity observed has
been precipitation of the drug in the kidney following rapid infu-
sion, leading to renal failure. Thus, Ga is a well-establishedmedic-
inal metal with an established safety profile.
We have previously shown that Ga inhibits the in vitro growth
of M. tuberculosis and Mycobacterium avium complex bacteria
growing extracellularly or in human macrophages (6). We now
extended the previous work by examining the efficacy of Ga in
murine models of pulmonary M. tuberculosis infection. To pro-
vide a highly discriminating and rapid assay to determine the im-
pact of Ga on the course of M. tuberculosis infection in mice, we
used BALB/c SCID mice in our initial set of experiments. BALB/c
SCID mice lack functional B and T cells but exhibit normal func-
tion of myeloid cells, antigen-presenting cells, and natural killer
(NK) cells (33). SCID mice have been used previously to study
chronic infections and infections caused by intracellular patho-
gens, including M. tuberculosis (34, 35). The lack of functional B
and T cells in SCID mice makes them highly susceptible to infec-
tions caused by intracellular pathogens, includingM. tuberculosis
(Fig. 1). As expected, controlmice infected i.t. withM. tuberculosis
succumbed to infection over a matter of weeks in proportion to
the initial inoculum ofM. tuberculosis. Daily administration of Ga
i.p. markedly extended the life span of theM. tuberculosis-infected
animals compared to the controls, regardless of whether a low- or
high-dose inoculum of M. tuberculosis was used.
PulmonaryM. tuberculosis infection of mice leads to rapid dis-
semination of the organism to other organs (Fig. 2). Ga adminis-
tration significantly decreased the level of M. tuberculosis in the
lungs (89.9%), liver (97.7%), and spleen (84.8%) in SCID mice.
This magnitude of decrease of M. tuberculosis CFU with Ga was
less than the profound effect on survival. One interpretation of
these data is that in addition to its direct antimicrobial activity, Ga
may enhance the effectiveness of the host immune system to kill
the organism. In immunocompromised animals, the latter effect
of Ga may be absent.
In our second set of experiments, the effect of Ga onM. tuber-
culosis infection in standard BALB/c mice was examined. As ex-
pected from the literature (36), i.t. infection of BALB/cmice led to
a chronic nonlethal infection that also resulted in a loss of weight
of the infected animals over time (Fig. 3). Animals treated with Ga
for 30 days exhibited less weight loss, and the number of viableM.
tuberculosis CFU in lung and other tissues was significantly de-
creased (Fig. 3). The magnitude of the CFU difference is less than
that reported for other standard antibiotics, such as rifampin and
isoniazid (37). Our in vivo results are also somewhat contrary to
our previous work, which showed that Ga treatment led to a sev-
eral-log decline in CFU in human MDM in vitro relative to un-
treated controls (30). Clearly,morework is needed to optimize the
dosing regimen of Ga in this murine model before valid compar-
isons with other agents can be made. Our laboratory and others
have shown the ability of Ga(NO3)3 to inhibit the growth of my-
FIG 4 Gallium inhibitsM. tuberculosis RR activity. RR activity inM. tubercu-
losis was measured as described in Materials and Methods. M. tuberculosis
H37Ra bacteria were treated with different concentrations of Ga for 24 h. Inhi-
bition of RR was seen at all levels of Ga treatment relative to the control (P
0.05). The inhibition increased significantly when the Ga concentration was
doubled from10 to 20M.However, further inhibitionwas not seenwhen the
Ga treatment dose was increased to 50 or 100 M. Asterisks indicate a P value
of0.05 (n	 5).
FIG 5 Gallium inhibitsM. tuberculosis aconitase activity. Aconitase activity in
M. tuberculosis was measured as described in Materials and Methods. M. tu-
berculosis bacteria were incubated in defined 7H9 medium that was supple-
mented with 1M ferric ammonium citrate alone or with the desired concen-
trations of Ga(NO3)3 for 24 h, following which the organisms were harvested
and aconitase activity was determined. Ga-mediated concentration-depen-
dent inhibition of M. tuberculosis aconitase activity was observed. Asterisks
indicate a P value of0.05 (n	 4 to 7 for each group).
Olakanmi et al.
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cobacteria and other bacteria (6, 38). It is possible that the bacte-
riostatic effect of Ga on mycobacteria is related in part to the
inactivation of bacterial Fe-centered enzymes such as aconitase
and RR.
The efficacy of Ga in murine TB is consistent with results re-
ported previously for other types of bacterial infections. We have
previously shown that Ga is protective in murine lung infection
models with both Pseudomonas aeruginosa (16) and Francisella
tularensis (17). Others have reported various forms of Ga to be
effective in a murine P. aeruginosa burn infection model (39) and
in infections caused by Rhodococcus equi (40) and Acinetobacter
baumannii (5).
The animal studies reported here provide an in vivo proof of
principle that Ga could prove to be effective in the treatment ofM.
tuberculosis infection. Ga’s ability to substitute for iron in iron-
dependentmetabolic pathways represents a fundamental new tar-
get approach to treatment. Having said this, further enhancement
of the potency of Ga against M. tuberculosis requires a better un-
derstanding of the specific microbial target(s) of Ga. Our previ-
ously reported findings that Ga inhibition of M. tuberculosis
growth correlates directly with disruption of bacterial iron uptake
(30) led us to study the possible effect of Ga on iron-dependent
enzymes such as RR, which is essential for DNA synthesis (23).
Eukaryotic RR was previously shown to be the key target of the
anticancer effect of Ga (23).M. tuberculosis contains both class Ib
and class II ribonucleotide reductases (24). In the present work,
we found concentration-dependent inhibition of M. tuberculosis
RR activity at Ga concentrations at or below those leading to
growth inhibition. However, inhibition plateaued at approxi-
mately 50% of RR activity, even at concentrations of Ga that com-
pletely inhibited growth (Fig. 4).
These data provide evidence that the ability of Ga to inhibit RR
could contribute to the growth-inhibitory effect of Ga on M. tu-
berculosis. Previous work has shown that the class Ib, but not the
class II, RR enzyme is essential for growth ofM. tuberculosis (24).
The loss of the class Ib RR enzyme in M. tuberculosis is not com-
pensated for by the presence of the type II RR (24). The discrep-
ancy between the relativemagnitudes of RR inhibition and growth
inhibition by Ga raises the possibility that Ga selectively inhibits
the class Ib enzyme of RR and not class II. However, further in-
vestigation is needed to identify the specific RR(s) targeted by Ga
and the mechanism(s) of inhibition.
Importantly, our previous and current data provide evidence
for the specificity of Ga forM. tuberculosisRR in the context of TB
infection. In this regard, macrophages are terminally differenti-
ated cells and have minimal to no RR activity, and our previous
work showing no toxicity of Ga for human macrophages is con-
sistent with this (6). Also, the safety portfolio forGa is good for the
FDA indications (15).
Our data also suggest that in addition to RR, inhibition of
another important iron-dependent enzyme could contribute to
the ability of Ga to inhibit M. tuberculosis growth. M. tuberculosis
aconitase catalyzes the isomerization of citrate to isocitrate in the
TCA cycle and acts as an RNA-binding protein (27). We found
that Ga treatment inhibited aconitase in a dose-dependent man-
ner. Thus, this inhibition may be an additional mechanism of Ga
action onM. tuberculosis. Given the multitude of iron-dependent
enzymes in bacteria, it is likely that Ga inhibits several such M.
tuberculosis enzymes.We have previously shown that growth of F.
tularensis in the presence of Ga leads to a decrease in the activities
of both catalase and iron superoxide dismutase (17). Additional
work is needed to assess which of the multiple potential targets is
most critical to the antimicrobial effect of Ga, and this may vary
with the bacterial species being studied. For example, preliminary
data suggest that Ga has no effect on F. tularensis aconitase activity
at concentrations that completely inhibit bacterial growth (O.
Olakanmi and B. E. Britigan, unpublished data).
In summary, the current study provides further evidence that
Ga has promise as an antimycobacterial chemotherapeutic agent
that likely acts by interfering with iron uptake and utilization by
M. tuberculosis. The current work was undertaken using
Ga(NO3)3 because it is the FDA-approved formulation of Ga that
is approved for use in humans and has an established safety pro-
file. However, alternative, more potent Ga formulations and de-
livery systems are worth examining. Previous work by Stojiljkovic
et al. (18) suggested that Ga-protoporphyrin complexes exhibit
potent activity against mycobacteria in vitro, an observation that
we have recently confirmed (B. L. Switzer,M. Y. Abdalla, and B. E.
Britigan, unpublished data). An oral formulation of Ga in the
form of Ga-maltolate has been developed and appears to have
good absorption from the gastrointestinal tract and bioactivity
(3). Ga represents a new class of antibiotics with some specificity
and is cheap to produce. Further efforts to identify and developGa
formulations that optimize the antimicrobial effect while limiting
toxicity to the host are needed and are underway in our laboratory
and those of other investigators.
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